<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404779</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0225</org_study_id>
    <secondary_id>2014-004951-30</secondary_id>
    <nct_id>NCT02404779</nct_id>
  </id_info>
  <brief_title>Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents</brief_title>
  <acronym>THIC Cu</acronym>
  <official_title>Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Severely brain injured patients are at high risk of intracranial hypertension. Among medical
      treatments (sedatives), neuromuscular blocking agents (NMBA) are recommended by french but
      not english speaking societies.

      Effects of NMBA are unknown. The present study is designed to compare the effects of NMBA
      versus placebo in the treatment of intracranial hypertension, and the underlying
      physiopathologic effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In case of intracranial hypertension, french neurocritical care society argue for the use of
      neuromuscular blocking agents before osmotherapy, barbituric coma, hypothermia and
      craniectomy.

      English speaking societies don't sustain this approach. Since then, the use of NMBA remains
      controversial in case of intracranial hypertension and no study is available.

      We propose to study severely brain injured patients presenting with intracranial hypertension
      and treat them with cisatracurium besilate or placebo.

      Our hypothesis is that neuromuscular blockade might act on several parameters:

        -  Hemodynamics

        -  respiratory parameters, mechanical ventilation and blood gaz analysis

        -  cerebral velocities

        -  diminished O2 peripheral consumption

        -  cerebrospinal diffusion and concentration of cisatracurium and a metabolite laudanosine
           We wish to assess changes in ICP according to the above parameters in a controlled
           randomized non blinded fashion against placebo (NaCl 0,9%).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve of the temporal evolution of intracranial pressure</measure>
    <time_frame>at day 1</time_frame>
    <description>The primary outcome is the area under the curve of the temporal evolution of intracranial pressure, over a period of 30 minutes after the administration of neuromuscular blocking agent or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Course of intracranial and cerebral perfusion pressures and various cerebral monitoring data if available (SvjO2, PtiO2)</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of the time spent by intracranial pressure above 20 mmHg using continuous recording</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of intracranial pressure based on the type of brain injury</measure>
    <time_frame>at day 1</time_frame>
    <description>diffuse axonal injury, subarachnoid hemorrhage, intracerebral hematoma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of the curare effect</measure>
    <time_frame>at day 1</time_frame>
    <description>train of four and PTC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of ventilation parameters</measure>
    <time_frame>at day 1</time_frame>
    <description>tidal volume, FiO2, PEEP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of transcranial Doppler data</measure>
    <time_frame>at day 1</time_frame>
    <description>velocities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of arterial blood gas data</measure>
    <time_frame>at day 1</time_frame>
    <description>pH, paO2, paCO2, Excess Base, HCO3-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of plasma and cerebrospinal fluid concentrations of cistracurium and laudanosine</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid concentrations of cisatracurium and laudanosin in case of cerebrospinal fluid derivation</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiovascular complications</measure>
    <time_frame>at day 1</time_frame>
    <description>hypotension, myocardial ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of pulmonary complications</measure>
    <time_frame>at day 1</time_frame>
    <description>acute respiratory distress syndrome, pneumonia acquired under mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of renal complications</measure>
    <time_frame>at day 1</time_frame>
    <description>use of renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of infectious complications</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of vasopressors or catecholamines</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need to increase therapeutics</measure>
    <time_frame>at day 1</time_frame>
    <description>barbiturate coma, hypothermia, osmotherapy, decompressive craniectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Intracranial Hypertension</condition>
  <arm_group>
    <arm_group_label>CISATRACURIUM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisatracurium besilate</intervention_name>
    <arm_group_label>CISATRACURIUM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age over 18

          -  Mechanical ventilation and deep sedation

          -  Severe traumatic brain injury

          -  Intracranial hypertension (ICP &gt; 20 mmHg during &gt; 15 minutes)

          -  Intracranial pressure monitoring

          -  Hemodynamically stable

        Exclusion Criteria:

          -  - History of anaphylaxia with neuromuscular agents

          -  Hemodynamic instability

          -  Pregnant and/or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie KAUFFMANN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU</keyword>
  <keyword>Deep sedation</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Traumatic brain injury</keyword>
  <keyword>Intracranial hypertension</keyword>
  <keyword>Cisatracurium</keyword>
  <keyword>Neuromuscular Blocking Agent</keyword>
  <keyword>Randomization versus placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Intracranial Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisatracurium</mesh_term>
    <mesh_term>Atracurium</mesh_term>
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

